Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) – Investment analysts at Jefferies Group increased their FY2017 EPS estimates for shares of Vertex Pharmaceuticals in a research report issued on Wednesday. Jefferies Group analyst B. Abrahams now anticipates that the firm will earn $1.27 per share for the year, up from their prior estimate of $1.14. Jefferies Group currently has a “Buy” rating and a $104.00 price target on the stock.

A number of other equities research analysts have also commented on the company. Zacks Investment Research lowered Vertex Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, September 27th. Citigroup Inc. started coverage on Vertex Pharmaceuticals in a research report on Tuesday, September 13th. They issued a “market perform” rating on the stock. They noted that the move was a valuation call. Credit Suisse Group AG reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, June 16th. Leerink Swann reiterated an “outperform” rating and issued a $113.00 price objective on shares of Vertex Pharmaceuticals in a research report on Thursday, September 15th. Finally, Vetr upgraded Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $94.50 price objective on the stock in a research report on Monday, June 27th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $117.60.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded up 0.87% during trading on Friday, hitting $85.70. The company had a trading volume of 983,269 shares. The stock’s market cap is $21.23 billion. Vertex Pharmaceuticals has a 12-month low of $75.90 and a 12-month high of $134.71. The firm has a 50 day moving average of $92.75 and a 200 day moving average of $89.81.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.24 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.03. The business had revenue of $431.61 million for the quarter, compared to analysts’ expectations of $428.08 million. Vertex Pharmaceuticals had a negative return on equity of 12.34% and a negative net margin of 17.77%. The company’s quarterly revenue was up 159.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.54) EPS.

Several large investors have recently added to or reduced their stakes in the stock. FMR LLC increased its position in shares of Vertex Pharmaceuticals by 46.9% in the second quarter. FMR LLC now owns 22,227,104 shares of the pharmaceutical company’s stock valued at $1,911,975,000 after buying an additional 7,092,351 shares in the last quarter. Capital World Investors increased its position in shares of Vertex Pharmaceuticals by 0.4% in the second quarter. Capital World Investors now owns 21,692,797 shares of the pharmaceutical company’s stock valued at $1,866,014,000 after buying an additional 94,635 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Vertex Pharmaceuticals by 2.2% in the second quarter. Vanguard Group Inc. now owns 15,265,175 shares of the pharmaceutical company’s stock valued at $1,313,110,000 after buying an additional 329,337 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Vertex Pharmaceuticals by 4.2% in the second quarter. JPMorgan Chase & Co. now owns 12,173,439 shares of the pharmaceutical company’s stock valued at $1,047,161,000 after buying an additional 485,112 shares in the last quarter. Finally, State Street Corp increased its position in shares of Vertex Pharmaceuticals by 0.4% in the second quarter. State Street Corp now owns 9,825,708 shares of the pharmaceutical company’s stock valued at $845,214,000 after buying an additional 35,700 shares in the last quarter. Institutional investors own 96.19% of the company’s stock.

In other news, Director Joshua S. Boger sold 900 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $100.19, for a total value of $90,171.00. Following the completion of the sale, the director now directly owns 268,225 shares in the company, valued at $26,873,462.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Joshua S. Boger sold 6,500 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, July 13th. The shares were sold at an average price of $88.81, for a total transaction of $577,265.00. Following the completion of the sale, the director now owns 274,725 shares of the company’s stock, valued at $24,398,327.25. The disclosure for this sale can be found here. Company insiders own 1.90% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

5 Day Chart for NASDAQ:VRTX

Receive News & Stock Ratings for Vertex Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.